Polyphron will use Cellino’s induced pluripotent stem cells in its “autonomous tissue foundry” to reproducibly manufacture cell and tissue therapies at scale.
The new CellFiber Extruder aims to address manufacturing bottlenecks in cell therapy by enabling scalable, GMP-compliant cell production.
The proposed legislation, if passed, will allow culture-expanded autologous mesenchymal stem cell therapies in the Cowboy State.
Based on Phase IIa trial data where 85% of patients had resolution of chronic fatigue over 20% with placebo, the company will now offer its cord blood cell therapy outside of the Phase III soon.
The company’s autologous cartilage repair product will now be reimbursed under national health insurance, WOMAC scores improved better than hyaluronic acid injections.
Researchers report that intranasal Muse cells improved motor function and reduced neurodegeneration in a Parkinson’s mouse model.
Stemchymal’s CDMO has been selected, while the company seeks conditional approval in both Japan and Taiwan following Phase II results.
Resbiomed, a placental collagen materials manufacturer, is working on scaling up production for what appears regenerative ophthalmology in Europe.
The trial found no significant difference in pain or function outcomes between bone marrow injections and sham procedures over 12 months, but also had important limitations.
The new platforms aim to streamline large-scale production of iPSC-derived cell therapies for new indications.
After stepping back from stem cell therapies last year, Novo is passing the torch on diabetes cell therapies to Aspect Biosystems, who will continue to commercialize the tech.
OpCT-001 is an iPSC-derived cell therapy for retinitis pigmentosa, and it’s now entering clinical testing following Orphan Drug status.
Polyphron will use Cellino’s induced pluripotent stem cells in its “autonomous tissue foundry” to reproducibly manufacture cell and tissue therapies at scale.
The new CellFiber Extruder aims to address manufacturing bottlenecks in cell therapy by enabling scalable, GMP-compliant cell production.
The proposed legislation, if passed, will allow culture-expanded autologous mesenchymal stem cell therapies in the Cowboy State.
Based on Phase IIa trial data where 85% of patients had resolution of chronic fatigue over 20% with placebo, the company will now offer its cord blood cell therapy outside of the Phase III soon.
The company’s autologous cartilage repair product will now be reimbursed under national health insurance, WOMAC scores improved better than hyaluronic acid injections.
Researchers report that intranasal Muse cells improved motor function and reduced neurodegeneration in a Parkinson’s mouse model.
Stemchymal’s CDMO has been selected, while the company seeks conditional approval in both Japan and Taiwan following Phase II results.
Resbiomed, a placental collagen materials manufacturer, is working on scaling up production for what appears regenerative ophthalmology in Europe.
The trial found no significant difference in pain or function outcomes between bone marrow injections and sham procedures over 12 months, but also had important limitations.
The new platforms aim to streamline large-scale production of iPSC-derived cell therapies for new indications.
After stepping back from stem cell therapies last year, Novo is passing the torch on diabetes cell therapies to Aspect Biosystems, who will continue to commercialize the tech.
OpCT-001 is an iPSC-derived cell therapy for retinitis pigmentosa, and it’s now entering clinical testing following Orphan Drug status.
